African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?
about
Vitamin D and Immune Response: Implications for Prostate Cancer in African AmericansActive surveillance and focal therapy for low-intermediate risk prostate cancerMultiparametric prostate magnetic resonance imaging in the evaluation of prostate cancerCurrent state of prostate cancer treatment in JamaicaActive surveillance for prostate cancer: current evidence and contemporary state of practiceIs active surveillance a suitable option for African American men with prostate cancer? A systemic literature review.Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American menThe use of exome genotyping to predict pathological Gleason score upgrade after radical prostatectomy in low-risk prostate cancer patientsReducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American menActive surveillance in men with low-risk prostate cancer: current and future challenges.Reclassification rates are higher among African American men than Caucasians on active surveillanceRacial disparities in oncologic outcomes after radical prostatectomy: long-term follow-upClinical and biochemical outcomes of men undergoing radical prostatectomy or radiation therapy for localized prostate cancer.Applying precision medicine to the active surveillance of prostate cancer.Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer.Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical ProstatectomyAfrican American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men.The Elimination of Cancer Health Disparities: Are We Ready to Do the Heavy Lifting?Role of neutrophil-to-lymphocyte ratio in prediction of Gleason score upgrading and disease upstaging in low-risk prostate cancer patients eligible for active surveillanceVery-high-risk localized prostate cancer: definition and outcomes.Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence.Management of low risk prostate cancer-active surveillance and focal therapy.Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.Racial-Sex Disparities--A Challenging Battle Against Cancer Mortality in the USA.Current trends and new frontiers in focal therapy for localized prostate cancer.Expectant management for men with early stage prostate cancer.Anterior prostate biopsy at initial and repeat evaluation: is it useful to detect significant prostate cancer?Active Surveillance for Intermediate Risk Prostate Cancer.Prostate cancer in men of African origin.Prostate cancer screening practices in a large, integrated health system: 2007-2014.Australian validation of the Cancer of the Prostate Risk Assessment Post-Surgical score to predict biochemical recurrence after radical prostatectomy.Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy.Disparities in staging prostate magnetic resonance imaging utilization for nonmetastatic prostate cancer patients undergoing definitive radiation therapy.Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database.Racial/Ethnic Disparity in Treatment for Prostate Cancer: Does Cancer Severity Matter?Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer.A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate.Racial/ethnic differences in the relative risk of receipt of specific treatment among men with prostate cancerRole of active surveillance and focal therapy in low- and intermediate-risk prostate cancers.Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.
P2860
Q26768536-3D4E0EFA-57EF-4182-8D08-AEB6D378E566Q26773641-382B88FE-1624-48E5-88FE-1D81FC46D501Q26776478-63712594-970E-4BD6-819C-B3E015AB8065Q26830148-902C2F98-E344-407D-8E35-9941ABC84E64Q28066534-40839051-44D1-4498-84B1-D269A28C17FBQ30234760-4ED520D0-52DD-444D-AE10-0DF543F70B72Q33702311-B98ABEFC-3BC1-4413-B1C4-337B3940EA4FQ34004995-FE13BCEB-053F-4D9A-B14B-2AD1B0875C42Q34171025-B936E8EA-1C17-4F26-AAF1-9FB4F715B0FCQ34448113-4BFD5A09-BCC3-46B9-BC19-2C17AC357E63Q34765233-AA6F5145-8A9B-4696-A54F-E29814D6CCC8Q35111951-8F3DD9CB-8F1F-4329-9ABC-4E306D1B8014Q35375249-5C0F10B3-D6FF-474D-B866-C4AB6015A0C8Q36592871-9A857D85-504E-4578-9DB8-BA5580697F57Q36892392-422749A1-4EF4-44BA-B40F-D792A27C0C05Q36915269-BD355F36-E622-4A41-AEB3-794AF5435D79Q37167067-F4FCD17A-54F3-4894-8252-B7B96D65F83DQ37496665-E3E43307-DEDE-46AC-863A-10910391E913Q37585270-70B16B53-423D-4134-ADC2-38134FE41D92Q37623723-1284ED0A-B82E-47B4-A507-ADA87DAEF264Q37735433-BC895747-DA6D-4ED7-8B2E-DCF3E9D7050DQ38211360-24278FA1-E5A7-4204-B9F8-945CA858571BQ38391188-444DE4DD-54DF-4A76-AECA-00D36D842C22Q38409742-87E0E0FA-F38D-4C06-86EA-97693D6A6468Q38436625-D539AD30-66EE-489C-B0AF-91CE515303F0Q38469754-803E16DD-A285-4676-A4F7-9E6134339374Q38532432-8B216C80-400E-477A-B3D1-605BAD06B875Q38627996-A6E15E85-3040-4A81-8AD5-7BE11975B646Q38683379-7454E99E-83CF-482C-8A22-93C943DBE878Q38764041-82E8026C-E1DC-44EF-B029-34948C90E197Q38805275-AA6D8662-62D3-4401-9E45-6772D819CBF7Q39648538-463D0B69-FD51-4F3E-9F31-DC59F4C8B153Q40109688-2E7D10F1-DE9A-4F2B-8489-FDF9989FD707Q40561460-1ED1CDCD-9B9D-4E98-9327-F59E78C9459FQ40566372-ECE95885-4535-47E1-99B0-8C6589280839Q40636362-0B713F80-590C-4A78-BDB8-B8514C905A49Q40739449-8EF67A50-EF58-4F61-AA97-7303B639E70CQ40762402-755D3859-AC27-41F9-8FEB-D06781F627F2Q40875442-9B8828AA-6E86-4D98-8508-60A820B24C81Q41564129-E245DEB3-5A83-4ABF-9BCA-2CDEED1C0CEB
P2860
African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
African American men with very ...... e still be an option for them?
@en
African American men with very ...... e still be an option for them?
@nl
type
label
African American men with very ...... e still be an option for them?
@en
African American men with very ...... e still be an option for them?
@nl
prefLabel
African American men with very ...... e still be an option for them?
@en
African American men with very ...... e still be an option for them?
@nl
P2860
P50
P356
P1476
African American men with very ...... e still be an option for them?
@en
P2093
Elizabeth B Humphreys
H Ballentine Carter
P2860
P304
P356
10.1200/JCO.2012.47.0302
P407
P577
2013-06-17T00:00:00Z